Pier-Anne Lachance

Dr. Lachance serves as the Director of Quality Control and Product Development at Genprex, leading the development of a control strategy for Genprex’s programs. She has spent her industry career of more than 10 years in the development and manufacturing of cell and gene therapies. Prior to joining Genprex in May 2022, Dr. Lachance was Associate Director of Quality Control at Immatics Inc. where she built the Quality Control unit from the ground up, to a laboratory of more than 10 analysts and designed the systems to ready products for a phase III clinical trials. In her prior role, Dr. Lachance played a pivotal role in the establishment of the Houston site Lonza Biologics, Inc. as a member of the core buildout team representing Quality Control for the establishment of the manufacturing plant designated for cell and gene therapies, in addition to overseeing quality control activities to prepare clients for BLA submission of key cell therapy products.

Dr. Lachance earned her Ph.D. in Physiology and Biophysics from Baylor College of Medicine, Houston TX., with her research focused on the role of the immune system plasticity in inflammation and circulation of macrophages and the role of integrins in vessel remodeling. She also received a Canadian Institute of Health Research Doctoral Research Award for her doctoral work.